Pipeline

Calyxha is developing novel small molecule anti-inflammatory drugs.

CAL-4 is being developed by Calyxha as an inhaled drug initially for asthma, and is due to enter the clinic in 2023. CAL-4 is predicted to bring the benefit of steroid treatment, but without affecting the cellular pathways involved in steroid side-effects.

Candidate

Indication

Discovery

Preclinical

Clinical

CAL-4

Asthma

Phase 1

2024

CAL-4

Neuro-degenerative diseases

CAL-4

COPD

CAL-4

Allergy

CAL4

CAL-4 is a calixarene small molecule drug identified by Calyxha’s CSO, Professor Robert Konrat using a computation approach integrating several software tools and novel biological pathways to identify potential novel anti-inflammatory drugs.

CAL-4 acts as an inflammatory inhibitor through mimicking the naturally occuring heparan sulphate.